Obese, Pregnancy, Sleep Disordered Breathing
Conditions
Brief summary
The purpose of this study is to better understand how sleep apnea, a common sleep disorder in which a person has one or more pauses in breathing or shallow breaths while sleeping, may affect pregnancy and to determine the effect of Continuous Positive Airway Pressure (CPAP), a treatment that uses mild air pressure to keep the airways open during sleep, for pregnant women with sleep apnea.
Detailed description
Emerging data support a link between sleep disordered breathing (SDB) and adverse pregnancy outcomes, particularly preeclampsia. Furthermore, SDB, which is characterized by intermittent nocturnal hypoxia-reoxygenation as well as sleep disruption, results in endothelial dysfunction and metabolic dysregulation, the same biological pathways that have been associated with adverse pregnancy outcomes. Obesity is a well-known risk factor for both adverse pregnancy outcomes and SDB, and has been associated with the same aforementioned biological aberrations. Therefore, obesity complicates the definition of a causal relationship between SDB and pregnancy outcomes. While some classic cardiovascular risk factors (prehypertension) are certainly relevant in pregnancy, there are also well-established risk factors that are unique to pregnancy (uterine vascular stiffness, placental angiogenic factors). The interplay between SDB, obesity and these unique cardiovascular risk factors remains undefined, and this proposal aims to address this knowledge gap. Without this data, our ability to understand how we can mitigate these risks through the use of therapeutic interventions for SDB, such as CPAP (continuous positive airway pressure), is compromised. To further address this knowledge gap, we will make use of the placenta's ability to accumulate evidence of damage over time and provide a record of maternal vascular health throughout gestation. Numerous placental lesions deriving from maternal vascular disease have been identified and can be readily detected on placental pathology. These lesions can provide a measure of the severity of hypoxic stress experienced by the fetus during gestation. The investigators' central hypothesis is that SDB is an effect modifier that increases maternal cardiovascular risk and placental hypoxic injury in obese pregnant women, and that CPAP treatment during pregnancy will result in an improved cardiovascular risk and placental profile. To test this hypothesis the investigaotrs will identify a cohort of obese women both with and without SDB. The investigators will examine SDB's impact on maternal vascular stiffness (uterine artery Doppler), angiogenesis (pregnancy specific angiogenic factors e.g., sFLT-1) and metabolism (insulin resistance) across pregnancy (Aim 1). The investigators will perform a randomized controlled trial of autotitrating- CPAP verses sham-CPAP in pregnancy to examine the impact of CPAP treatment during pregnancy on cardiovascular risk (Aim 2) and will explore the interplay between SDB, CPAP and evidence of maternal vascular disease and chronic fetal hypoxia by evaluating the placental profile of obese women with and without SDB (Aim 3).
Interventions
CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
Information about sleep apnea and healthy sleep. Information about local sleep resources
Sponsors
Study design
Eligibility
Inclusion criteria
* women between 14 0/7 and 20 6/7 weeks gestation at the time of their initial PSG assessment. * Pregnancy and current BMI \>=30 * Self-reported frequent snoring (\>=3x/week over past month) or self-reported non-snorer.
Exclusion criteria
* diagnosis of pregestational diabetes. * self-report a history of sleep apena and who are using or were receommended by a physican to use a PAP device already * twins
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | early pregnancy (14-16 weeks gestation) | The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity. |
| Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | early pregnancy (14-16 weeks gestation) | Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5) |
| Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | early pregnancy (14-16 weeks gestation) | sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Placental Histology and Immunohistochemistry | After delivery (expected 37-40 weeks gestation) | placental histology and immunohistochemistry |
Other
| Measure | Time frame | Description |
|---|---|---|
| Mean Arterial Blood Pressure (mmHg) Angiogenic Domain | early pregnancy (14-16 weeks gestation) | — |
| Soluble Endoglin (sEng , pg/mL)-Blood Measurement | late pregnancy (28-32 weeks gestation) | Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts |
| Soluble Endoglin (sEng ,pg/mL)-Blood Measurement | early pregnancy (14-16 weeks gestation) | Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts |
| Pregnancy Outcome Data | At time of delivery (expected 37-40 weeks gestation) | Preeclampsia, Gestational diabetes, Gestational age at delivery, Indication for delivery, Birthweight, Cord gases |
Countries
United States
Participant flow
Pre-assignment details
A total of 452 individuals were screened and 355 participants consented for this study . Prior to or during the inital study visit, 113 individuals withdrew or were withdrawn from the study. 242 participants completed visit 1 (14 0/7-20 6/7 weeks gestation, mean gestational age 18.1 ± 2.0 weeks), of whom 89 (37%) had an AHI between 5 and 50 and therefore were eligible for randomization.
Participants by arm
| Arm | Count |
|---|---|
| Obese, SDB Postive, Sham-CPAP Sham (non-therapeutic) CPAP
sham-CPAP | 26 |
| Obese, SDB Postive, CPAP, Phase 1 Therapeutic CPAP
CPAP: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing). | 25 |
| Obese, SDB Postive, Sleep Hygiene Sleep hygiene information and local sleep resources
Sleep hygiene: Information about sleep apnea and healthy sleep. Information about local sleep resources | 20 |
| Obese, SDB Positive, CPAP Phase 2 Therapeutic CPAP | 18 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 | 2 |
Baseline characteristics
| Characteristic | Obese, SDB Postive, Sham-CPAP | Total | Obese, SDB Positive, CPAP Phase 2 | Obese, SDB Postive, Sleep Hygiene | Obese, SDB Postive, CPAP, Phase 1 |
|---|---|---|---|---|---|
| Age, Continuous | 26.4 years STANDARD_DEVIATION 3.9 | 29.6 years STANDARD_DEVIATION 5.5 | 32.6 years STANDARD_DEVIATION 4.5 | 32.0 years STANDARD_DEVIATION 4.5 | 28.4 years STANDARD_DEVIATION 6.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 19 Participants | 57 Participants | 9 Participants | 13 Participants | 16 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 29 Participants | 9 Participants | 6 Participants | 9 Participants |
| Sex: Female, Male Female | 26 Participants | 89 Participants | 18 Participants | 20 Participants | 25 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 25 | 0 / 26 | 0 / 20 | 0 / 18 |
| other Total, other adverse events | 0 / 25 | 3 / 26 | 0 / 20 | 1 / 18 |
| serious Total, serious adverse events | 1 / 25 | 0 / 26 | 0 / 20 | 1 / 18 |
Outcome results
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin
Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5)
Time frame: early pregnancy (14-16 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 4.5 HOMA-IR score | Standard Deviation 3.5 |
| Obese, SDB Postive, CPAP, Phase 1 | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 4.6 HOMA-IR score | Standard Deviation 6.4 |
| Obese, SDB Postive, Sleep Hygiene | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 3.9 HOMA-IR score | Standard Deviation 2.2 |
| Obese, SBD Positive, CPAP, Phase 2 | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 4.2 HOMA-IR score | Standard Deviation 3 |
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin
Insulin resistance was calculated using the homeostatic model assessment for insulin resistance (HOMA-IR, fasting insulin (µU/mL) x fasting glucose (mmol/L) /22.5)
Time frame: late pregnancy (28-32 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 6.3 HOMA-IR score | Standard Deviation 10.7 |
| Obese, SDB Postive, CPAP, Phase 1 | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 3.7 HOMA-IR score | Standard Deviation 3.6 |
| Obese, SDB Postive, Sleep Hygiene | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 3.6 HOMA-IR score | Standard Deviation 1.8 |
| Obese, SBD Positive, CPAP, Phase 2 | Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)-Blood Measurement of Glucose and Insulin | 4.6 HOMA-IR score | Standard Deviation 6.3 |
Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement
sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia.
Time frame: early pregnancy (14-16 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 53.8 Ratio | Standard Deviation 29.1 |
| Obese, SDB Postive, CPAP, Phase 1 | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 65.1 Ratio | Standard Deviation 45.8 |
| Obese, SDB Postive, Sleep Hygiene | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 87.0 Ratio | Standard Deviation 69.1 |
| Obese, SBD Positive, CPAP, Phase 2 | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 88.3 Ratio | Standard Deviation 45 |
Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement
sFlt-1 is a splice variant of vascular endothelial growth receptor (VEGF) with antiangiogenic properties that is upregulated in preeclampsia. PlGF is an angiogenic cytokine that is highly expressed in the placenta. Low levels have been associated with preeclampsia.
Time frame: late pregnancy (28-32 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 30.5 Ratio | Standard Deviation 28.9 |
| Obese, SDB Postive, CPAP, Phase 1 | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 26.0 Ratio | Standard Deviation 18.3 |
| Obese, SDB Postive, Sleep Hygiene | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 38.3 Ratio | Standard Deviation 34.7 |
| Obese, SBD Positive, CPAP, Phase 2 | Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio-blood Measurement | 45.9 Ratio | Standard Deviation 57.3 |
Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound
The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity.
Time frame: early pregnancy (14-16 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 1.0 Mean PI | Standard Deviation 0.3 |
| Obese, SDB Postive, CPAP, Phase 1 | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 1.0 Mean PI | Standard Deviation 0.3 |
| Obese, SDB Postive, Sleep Hygiene | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 1.0 Mean PI | Standard Deviation 0.3 |
| Obese, SBD Positive, CPAP, Phase 2 | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 1.0 Mean PI | Standard Deviation 0.3 |
Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound
The uterine artery was located using color doppler imaging by placing the ultrasound probe in the right or left iliac fossa in the sagittal plane. The uterine artery was then identified where it crosses the external iliac artery. Doppler waveform was obtained using a sampling gate encompassing the width of the main uterine artery at an angle of insonation of \<30 degrees if possible. The PI was calculated using the formula: maximum-minimum velocity/mean velocity.
Time frame: late pregnancy (28-32 weeks gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese, SDB Postive, Sham-CPAP | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 0.9 Mean PI | Standard Deviation 0.2 |
| Obese, SDB Postive, CPAP, Phase 1 | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 0.8 Mean PI | Standard Deviation 0.3 |
| Obese, SDB Postive, Sleep Hygiene | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 0.8 Mean PI | Standard Deviation 0.2 |
| Obese, SBD Positive, CPAP, Phase 2 | Uterine Artery Doppler Mean Pulsatility Index -by Ultrasound | 0.7 Mean PI | Standard Deviation 0.1 |
Placental Histology and Immunohistochemistry
placental histology and immunohistochemistry
Time frame: After delivery (expected 37-40 weeks gestation)
Population: Placental collection and analysis was not performed due to inadequate staffing and personnel issues
Mean Arterial Blood Pressure (mmHg) Angiogenic Domain
Time frame: early pregnancy (14-16 weeks gestation)
Mean Arterial Blood Pressure (mmHg) Angiogenic Domain
Time frame: late pregnancy (28-32 weeks gestation)
Pregnancy Outcome Data
Preeclampsia, Gestational diabetes, Gestational age at delivery, Indication for delivery, Birthweight, Cord gases
Time frame: At time of delivery (expected 37-40 weeks gestation)
Soluble Endoglin (sEng , pg/mL)-Blood Measurement
Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts
Time frame: late pregnancy (28-32 weeks gestation)
Soluble Endoglin (sEng ,pg/mL)-Blood Measurement
Endoglin is a coreceptor for transforming growth factor beta-1 and beta-3 expressed on syncytiotrophoblasts
Time frame: early pregnancy (14-16 weeks gestation)